Separation and purification method of polypeptide with antioxidant function, polypeptide and application thereof
Through multi-brush roll interlacing and enzymatic lysis technology combined with chlorogenic acid graft chitosan reaction, the problem of insufficient stability and antioxidant ability of the peptide was solved, and the efficient extraction of antioxidant peptides with excellent performance was achieved.
Patent Information
- Application Number
- CN202411370725.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-09-29
AI Technical Summary
In the prior art, the molecular structure stability of polypeptides is poor and the antioxidant ability is relatively weak, making it difficult to meet the needs of efficient extraction and application.
The animal bones are brushed by a multi-brush roller staggered brushing device, combined with enzymatic lysis and ultrafiltration technology to obtain bone peptide liquid, and the reaction of chlorogenic acid grafted chitosan and transglutaminase is formed to form antioxidant functional polypeptides. Improve its stability and activity.
It improves the stability and antioxidant ability of the peptide, reduces the generation of impurities, improves the extraction efficiency and purity of components, and achieves the preparation of antioxidant peptides with excellent performance.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of polypeptide separation, and in particular to a method for separating and purifying a polypeptide with antioxidant function, a polypeptide and an application thereof. Background Art
[0002] Peptides are a class of compounds with a molecular structure between amino acids and proteins, which give proteins certain physiological functions. In human life activities, peptides are better digested and absorbed in the body than free amino acids, and have a different in vivo transport system from amino acids. Certain short peptides can prevent and treat diseases and regulate human functions while providing nutrients necessary for human growth and development. These biologically active peptides are called bioactive peptides.
[0003] Commonly used bioactive peptides in related technologies include animal-derived antioxidant peptides, which have strong effects on inhibiting the peroxidation of biological macromolecules and removing free radicals in the body. Antioxidant peptides are valued for their small molecular weight, easy absorption, and strong activity, and have broad prospects in medicine, cosmetics, health products, food and feed additives, etc.
[0004] In addition, the molecular structure of polypeptides is relatively unstable and needs to be improved during use; at the same time, the antioxidant capacity of polypeptide molecules extracted by related technologies is relatively poor. Application Contents
[0005] The present application is made in view of the above-mentioned problems, and its purpose is to provide a method for separating and purifying a polypeptide with antioxidant function, wherein the polypeptide obtained by this method has strong antioxidant capacity.
[0006] The first aspect of the present application provides a method for separating and purifying a polypeptide having an antioxidant function, comprising the following steps: S1. Brush the animal bones with a multi-brush roller staggered brushing device; S2, after the scrubbing is completed, the bone peptide solution is obtained by rinsing, enzymolysis and ultrafiltration; S3, mixing the bone peptide solution, chlorogenic acid grafted chitosan and transglutaminase, reacting, inactivating the enzyme, dialyzing, and drying after the dialysis is completed to obtain an antioxidant functional polypeptide; The mass ratio of the chlorogenic acid grafted chitosan and transglutaminase is 1:0.2-0.3; The mass volume ratio of the chlorogenic acid grafted chitosan and the bone peptide liquid is 1g:50mL~100mL.
[0007] According to one of the technical solutions of the present application, at least the following beneficial effects are achieved: First, use a multi-brush roller staggered scrubbing device to scrub the animal bones, and then rinse them. In the process, there is no need to manually remove the residual meat and grease, which is more labor-saving, relatively more efficient, and the cleaning effect is relatively more stable. The higher the purity of the raw materials, the less impurities will be produced after enzymatic hydrolysis. After inorganic membrane filtration, ultrafiltration membrane filtration is used to remove unnecessary macromolecular components and retain the required target components; the optimized enzymatic hydrolysis process releases the target molecules to the maximum extent, with high yield and high effective ingredients.
[0008] Chitosan molecules are first modified with chlorogenic acid, and then, under the catalysis of transglutaminase, animal bone peptides are connected to the amino groups on the chitosan molecules, thereby achieving the modification of bone peptides; The present application adds chlorogenic acid grafted chitosan to the polypeptide extract to form a protective barrier for the polypeptide active substance and improve the stability of the polypeptide substance, thereby preparing an antioxidant functional polypeptide with excellent performance.
[0009] According to some embodiments of the present application, the animal bone includes a bovine bone.
[0010] According to some embodiments of the present application, the brushing further includes acid leaching.
[0011] According to some embodiments of the present application, hydrochloric acid is used for acid leaching.
[0012] According to some embodiments of the present application, the mass fraction of the hydrochloric acid is 0.5%~1.5%.
[0013] According to some embodiments of the present application, the acid leaching time is 4h~6h.
[0014] According to some embodiments of the present application, the acid leaching treatment is followed by rinsing.
[0015] According to some embodiments of the present application, the flushing is high-pressure flushing.
[0016] According to some embodiments of the present application, the bone paste is obtained by crushing after flushing.
[0017] According to some embodiments of the present application, the enzymatic hydrolysis is a two-step enzymatic hydrolysis process, wherein: Neutral protease is used in the first step of enzymatic hydrolysis; In the second step of enzymatic hydrolysis, trypsin and flavor protease are used.
[0018] According to some embodiments of the present application, the activity unit of the neutral protease is 300,000 U / g to 600,000 U / g.
[0019] According to some embodiments of the present application, the activity unit of the trypsin is 300,000 U / g to 500,000 U / g.
[0020] According to some embodiments of the present application, the activity unit of the flavor protease is 300,000 U / g to 600,000 U / g.
[0021] According to some embodiments of the present application, the temperature of the enzymatic hydrolysis is 50°C to 60°C.
[0022] According to some embodiments of the present application, the mass ratio of the neutral protease to bone mud is 1~2:1000.
[0023] According to some embodiments of the present application, the mass ratio of trypsin to bone mud is 4~6:1000.
[0024] According to some embodiments of the present application, the mass ratio of the flavor protease to bone mud is 1~2:1000.
[0025] According to some embodiments of the present application, the temperature of the first step of enzymatic hydrolysis is 50°C to 60°C.
[0026] According to some embodiments of the present application, the time for the first step of enzymatic hydrolysis is 1 h to 3 h.
[0027] According to some embodiments of the present application, the temperature of the second step enzymatic hydrolysis is 50°C to 60°C.
[0028] According to some embodiments of the present application, the time of the second step enzymatic hydrolysis is 1h~3h.
[0029] According to some embodiments of the present application, the enzyme is inactivated after the enzymolysis is completed.
[0030] According to some embodiments of the present application, the temperature of the enzyme inactivation treatment is 95°C to 105°C.
[0031] According to some embodiments of the present application, the time for the enzyme inactivation treatment is 10 min to 15 min.
[0032] According to some embodiments of the present application, the enzyme inactivation treatment is followed by microfiltration.
[0033] According to some embodiments of the present application, the pore size of the filter membrane selected for microfiltration is 0.2 μm~0.3 μm.
[0034] According to some embodiments of the present application, the molecular weight cutoff of the ultrafiltration is 2000Da.
[0035] According to some embodiments of the present application, the method for preparing chlorogenic acid grafted chitosan comprises the following steps: Mixing chitosan, acetic acid, chlorogenic acid and vitamin C to prepare a first mixture; The first mixture and the hydrogen peroxide solution are mixed and reacted, dialyzed, and then freeze-dried.
[0036] Vitamin C reacts with hydrogen peroxide to generate hydroxyl radicals, which capture hydrogen atoms from chitosan molecules to form chitosan macromolecular free radicals. Chlorogenic acid molecules accept chitosan macromolecular free radicals to form chlorogenic acid-grafted chitosan.
[0037] According to some embodiments of the present application, the mass ratio of chitosan to chlorogenic acid is 1:0.5~1.
[0038] According to some embodiments of the present application, the mass ratio of chitosan to vitamin C is 1:0.05~0.2.
[0039] According to some embodiments of the present application, water is added during the preparation of the first mixture.
[0040] According to some embodiments of the present application, acetic acid and water are mixed to form an acetic acid solution.
[0041] According to some embodiments of the present application, the mass fraction of the acetic acid solution is 1%~3%.
[0042] According to some embodiments of the present application, the mass volume ratio of the chitosan and the acetic acid solution is 1 g: 50 mL to 100 mL.
[0043] According to some embodiments of the present application, the molar concentration of the hydrogen peroxide solution is 0.5 mol / L~1 mol / L.
[0044] According to some embodiments of the present application, the mass volume ratio of the chitosan and the hydrogen peroxide solution is 1 g: 5 mL~10 mL.
[0045] According to some embodiments of the present application, the molecular weight cutoff for dialysis during the preparation of the chlorogenic acid-grafted chitosan is 10,000 Da.
[0046] According to some embodiments of the present application, the reaction temperature in step S3 is 20°C to 30°C.
[0047] The second aspect of the present application provides a polypeptide, which is prepared by the separation and purification method described in the first aspect of the present application.
[0048] The third aspect of the present application provides the use of the polypeptide prepared in the second aspect of the present application in the preparation of antioxidant active substances. DETAILED DESCRIPTION
[0049] In order to make the purpose, technical solutions and advantages of the present application clearer, the present application is described and illustrated below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not intended to limit the present application. Based on the embodiments provided in the present application, all other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present application.
[0050] Obviously, the following descriptions are only some examples or embodiments of the present application. For ordinary technicians in this field, the present application can also be applied to other similar scenarios without creative work. In addition, it can also be understood that although the efforts made in this development process may be complicated and lengthy, for ordinary technicians in the field related to the content disclosed in this application, some changes in design, manufacturing or production based on the technical content disclosed in this application are just conventional technical means, and should not be understood as insufficient content disclosed in this application.
[0051] However, unnecessary detailed descriptions may be omitted. For example, detailed descriptions of well-known matters and repeated descriptions of substantially the same structures may be omitted. This is to avoid the following description from becoming unnecessarily lengthy and to facilitate understanding by those skilled in the art. In addition, the following description is provided for those skilled in the art to fully understand the present application and is not intended to limit the subject matter described in the claims.
[0052] If not otherwise specified, all embodiments and optional embodiments of the present application can be combined with each other to form a new technical solution.
[0053] Unless otherwise specified, all technical features and optional technical features of this application can be combined with each other to form a new technical solution.
[0054] "Scope" disclosed in the present application is limited in the form of lower limit and upper limit, and a given range is limited by selecting a lower limit and an upper limit, and the selected lower limit and upper limit define the boundary of a special range. The scope limited in this way can be including end values or not including end values, and can be arbitrarily combined, that is, any lower limit can be combined with any upper limit to form a scope. For example, if the scope of 60-120 and 80-110 is listed for a specific parameter, it is understood that the scope of 60-110 and 80-120 is also expected. In addition, if the minimum range values 1 and 2 are listed, and if the maximum range values 3, 4 and 5 are listed, the following scope can be all expected: 1-3, 1-4, 1-5, 2-3, 2-4 and 2-5. In the present application, unless otherwise specified, the numerical range "ab" represents the abbreviation of any real number combination between a and b, wherein a and b are real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" are listed in this document, and "0-5" is just an abbreviation of these numerical combinations. In addition, when a parameter is expressed as an integer ≥ 2, it is equivalent to disclosing that the parameter is, for example, an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.
[0055] If not otherwise specified, all embodiments and optional embodiments of the present application can be combined with each other to form a new technical solution.
[0056] Unless otherwise specified, all technical features and optional technical features of this application can be combined with each other to form a new technical solution.
[0057] If there is no special explanation, all steps of the present application can be performed sequentially or randomly, preferably sequentially. For example, the method includes steps (a) and (b), which means that the method may include steps (a) and (b) performed sequentially, or may include steps (b) and (a) performed sequentially. For example, the method may further include step (c), which means that step (c) may be added to the method in any order. For example, the method may include steps (a), (b) and (c), or may include steps (a), (c) and (b), or may include steps (c), (a) and (b), etc.
[0058] If there is no special explanation, the "include" and "comprising" mentioned in this application are open-ended or closed-ended. For example, the "include" and "comprising" may mean that other components not listed may also be included or only the listed components may be included or only the listed components may be included.
[0059] If not specifically stated, in this application, the term "or" is inclusive. For example, the phrase "A or B" means "A, B, or both A and B". More specifically, any of the following conditions satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist); A is false (or does not exist) and B is true (or exists); or both A and B are true (or exist).
[0060] The multi-brush roller staggered brushing device used in the embodiments and comparative examples of the present application uses the corresponding equipment in the embodiment of CN 202410117641.9.
[0061] Example 1 This embodiment is a method for separating and purifying a polypeptide having an antioxidant function, which consists of the following steps: S1. Brush the animal bones (cow bones) with a multi-brush roller staggered brushing device (brushing time is 30 minutes); S2, after scrubbing, pickling, washing and crushing to obtain bone mud; The acid leaching was carried out by immersing the bones in a hydrochloric acid solution with a mass fraction of 1% for 5 hours; the ratio of the cattle bones to the hydrochloric acid solution was 1kg:2L; Flushing adopts high pressure flushing, the flushing pressure is 10MPa, and the flushing time is 5min; The bone mud is enzymatically hydrolyzed, enzyme-inactivated, microfiltered (pore size of microfiltration is 0.22 μm) and ultrafiltered (molecular weight cutoff is 2000 Da) to obtain bone peptide solution; The enzymatic hydrolysis is a two-step enzymatic hydrolysis process, wherein: The first step of enzymatic hydrolysis uses neutral protease (activity unit: 400,000 U / g, the mass ratio of neutral protease to bone paste is 1:1000), the temperature of the first step of enzymatic hydrolysis is 55°C, the first step of enzymatic hydrolysis is performed in a neutral environment, and the time of the first step of enzymatic hydrolysis is 2 hours; The second step of enzymatic hydrolysis used a complex enzyme consisting of trypsin (activity unit: 300,000 U / g, the mass ratio of trypsin to bone paste is 4:1000) and flavor protease (activity unit: 500,000 U / g, the mass ratio of flavor protease to bone paste is 1:1000), the temperature of the second step of enzymatic hydrolysis was 55°C, and the time of the second step of enzymatic hydrolysis was 2h.
[0062] After the enzymatic hydrolysis is completed, the enzyme is inactivated (the temperature of the inactivation treatment is 100°C and the time is 15 min).
[0063] S3, mixing the bone peptide solution, chlorogenic acid grafted chitosan and transglutaminase, reacting (reaction temperature is 25°C, reaction time is 5h), inactivating the enzyme (enzyme inactivation treatment temperature is 100°C and time is 15min), dialyzing (retention molecular weight is 10000Da, dialysis time is 72h), and freeze-drying after dialysis to obtain antioxidant functional polypeptide; The preparation method of chlorogenic acid grafted chitosan in this embodiment comprises the following steps: Chitosan, an acetic acid aqueous solution (mass fraction of 2%, mass volume ratio of chitosan to acetic acid aqueous solution of 1 g: 50 mL), chlorogenic acid and vitamin C were mixed (mixing temperature of 25°C, mixing time of 30 min) to prepare a first mixture; The first mixture and hydrogen peroxide solution (1 mol / L, mass volume ratio of chitosan and hydrogen peroxide solution is 1 g:8 mL) were mixed and reacted (reaction temperature was 25°C, time was 24 h), dialyzed (retention molecular weight was 10000 Da, dialysis time was 72 h) and then freeze-dried.
[0064] The mass ratio of chitosan to chlorogenic acid is 1:0.8.
[0065] The mass ratio of chitosan to vitamin C is 1:0.1.
[0066] The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.28.
[0067] The mass volume ratio of chlorogenic acid grafted chitosan and bone peptide liquid is 1g:80mL.
[0068] Example 2 This example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 1 in that: The mass ratio of chitosan to chlorogenic acid is 1:0.5.
[0069] The mass ratio of chitosan to vitamin C is 1:0.2.
[0070] The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.2.
[0071] The mass volume ratio of chlorogenic acid grafted chitosan and bone peptide liquid is 1g:100mL.
[0072] Example 3 This example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 1 in that: The mass ratio of chitosan to chlorogenic acid is 1:1.
[0073] The mass ratio of chitosan to vitamin C is 1:0.05.
[0074] The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.3.
[0075] The mass volume ratio of chlorogenic acid grafted chitosan and bone peptide liquid is 1g:100mL.
[0076] Example 4 This example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 1 in that: The mass ratio of chitosan to chlorogenic acid is 1:0.6.
[0077] The mass ratio of chitosan to vitamin C is 1:0.15.
[0078] The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.21.
[0079] The mass volume ratio of chlorogenic acid grafted chitosan and bone peptide liquid is 1g:60mL.
[0080] Example 5 This example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 1 in that: The mass ratio of chitosan to chlorogenic acid is 1:0.5.
[0081] The mass ratio of chitosan to vitamin C is 1:0.05.
[0082] The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.2.
[0083] The mass volume ratio of chlorogenic acid grafted chitosan and bone peptide liquid is 1g:50mL.
[0084] Comparative Example 1 This comparative example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 5 in that: S3, mixing the bone peptide solution, chlorogenic acid grafted chitosan and transglutaminase, reacting (reaction temperature is 25°C, reaction time is 5h), inactivating the enzyme (enzyme inactivation treatment temperature is 100°C and time is 15min), dialyzing (retention molecular weight is 10000Da, dialysis time is 72h), and cooling and drying after dialysis to obtain antioxidant functional polypeptide; The preparation method of chlorogenic acid grafted chitosan in this comparative example comprises the following steps: Chitosan, an acetic acid aqueous solution (mass fraction of 2%, mass volume ratio of chitosan to acetic acid aqueous solution of 1 g: 50 mL) and chlorogenic acid were mixed (mixing temperature of 25°C, mixing time of 30 min) to prepare a first mixture; The first mixture and hydrogen peroxide solution (1 mol / L, mass volume ratio of chitosan and hydrogen peroxide solution is 1 g:8 mL) were mixed and reacted (reaction temperature was 25°C, time was 24 h), dialyzed (retention molecular weight was 10000 Da, dialysis time was 72 h) and then freeze-dried.
[0085] The mass ratio of chitosan to chlorogenic acid is 1:0.5.
[0086] The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.2.
[0087] The mass volume ratio of chlorogenic acid grafted chitosan and bone peptide liquid is 1g:50mL.
[0088] Comparative Example 2 This comparative example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 5 in that: S3, mixing the bone peptide solution, modified chitosan and transglutaminase, reacting (reaction temperature is 25°C, reaction time is 5h), inactivating the enzyme (enzyme inactivation temperature is 100°C and time is 15min), dialyzing (retention molecular weight is 10000Da, dialysis time is 72h), and cooling and drying after dialysis to obtain antioxidant functional polypeptide; The preparation method of modified chitosan in this comparative example comprises the following steps: Chitosan, an acetic acid aqueous solution (mass fraction of 2%, mass volume ratio of chitosan to acetic acid aqueous solution of 1 g: 50 mL) and vitamin C were mixed (mixing temperature of 25°C, mixing time of 30 min) to prepare a first mixture; The first mixture and hydrogen peroxide solution (1 mol / L, mass volume ratio of chitosan and hydrogen peroxide solution is 1 g:8 mL) were mixed and reacted (reaction temperature was 25°C, time was 24 h), dialyzed (retention molecular weight was 10000 Da, dialysis time was 72 h) and then freeze-dried.
[0089] The mass ratio of chitosan to vitamin C is 1:0.05.
[0090] The mass ratio of modified chitosan to transglutaminase is 1:0.2.
[0091] The mass volume ratio of modified chitosan and bone peptide liquid is 1g:50mL.
[0092] Comparative Example 3 This comparative example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 5 in that: S3, mixing the bone peptide solution, chitosan acetic acid mixture and transglutaminase, reacting (reaction temperature is 25°C, reaction time is 5h), inactivating the enzyme (enzyme inactivation treatment temperature is 100°C and time is 15min), dialyzing (retention molecular weight is 10000Da, dialysis time is 72h), and freeze-drying after dialysis to obtain antioxidant functional polypeptide; The preparation method of the chitosan acetic acid mixed solution in this comparative example comprises the following steps: Chitosan and acetic acid aqueous solution (mass fraction of 2%, mass volume ratio of chitosan to acetic acid aqueous solution of 1g:50mL) were mixed (mixing temperature of 25°C, mixing time of 30min) to prepare a chitosan acetic acid mixed solution.
[0093] The mass volume ratio of chitosan and bone peptide liquid is 1g:50mL.
[0094] Comparative Example 4 This comparative example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 5 in that: The mass ratio of chlorogenic acid grafted chitosan and transglutaminase was 1:0.1.
[0095] Comparative Example 5 This comparative example is a method for separating and purifying a polypeptide having an antioxidant function, which differs from Example 5 in that: S3. The bone peptide solution was dialyzed (molecular weight cutoff: 10,000 Da, dialysis time: 72 h), and after the dialysis was completed, it was freeze-dried to obtain antioxidant functional peptides.
[0096] The antioxidant test method is as follows: 1. Grouping and administration of drugs to zebrafish embryos 4hpf zebrafish embryos were randomly divided into a blank control group (without hydrogen peroxide), a H2O2 induction group (5mmol / L), and an experimental group (the antioxidant functional polypeptides prepared in the Examples and Comparative Examples, with a hydrogen peroxide concentration of 5mmol / L), with 50 embryos in each group.
[0097] Eight hours after zebrafish embryos were fertilized, the drug solution was prepared in fish culture water and incubated for 1 hour, and then the hydrogen peroxide concentration was controlled to 5 mM and incubated for 24 hours, and then changed to fish culture water for feeding.
[0098] 2. Zebrafish embryo survival rate At 48 hours, the embryo hatching rate was calculated and the heartbeat was maintained.
[0099] Survival rate = (hatched embryos / total number of fertilized eggs) × 100%, and the number of heartbeats within 1 minute was calculated; feeding continued for the third day and the experiment was conducted.
[0100] 3. ROS analysis in zebrafish embryos Select the shelled fry and place them in a 24-well plate; For DCFH-DA incubation, remove excess water from the well plate and replace with DCFH-DA with a final concentration of 500 μM for 30 min; After the DCFH-DA incubation was completed, the cells were washed twice with PBS.
[0101] Detection method: Fluorescence was detected by fluorescence microscopy, with an excitation wavelength of 488 nm and an emission wavelength of 525 nm.
[0102] The survival rate and ROS analysis results are shown in Table 1.
[0103]
[0104] Under normal physiological conditions, the content of ROS in zebrafish is low and can be cleared by the antioxidant defense system. ROS is mainly generated in mitochondria. When the production of ROS increases under oxidative stress and exceeds the clearance capacity of the body's antioxidant defense system, it will damage mitochondrial DNA and affect mitochondrial biosynthesis. During oxidative stress, the relationship between the content of reactive oxygen species in the body and the capacity of the antioxidant system is unbalanced, thus affecting the survival rate.
[0105] However, the ROS content in the examples of the present application is relatively low, indicating that the polypeptide in the present application improves the antioxidant capacity of zebrafish, thereby improving the survival rate of zebrafish.
[0106] It should be noted that the present application is not limited to the above-mentioned embodiments. The above-mentioned embodiments are only examples, and the embodiments having the same structure as the technical idea and exerting the same effect within the scope of the technical solution of the present application are all included in the technical scope of the present application. In addition, without departing from the scope of the main purpose of the present application, various modifications that can be thought of by those skilled in the art to the embodiments and other methods of combining some of the constituent elements in the embodiments are also included in the scope of the present application.
Claims
1. A method for separating and purifying a polypeptide having an antioxidant function, characterized in that: The following steps are involved: S1. Brush the animal bones with a multi-brush roller staggered brushing device; S2, after scrubbing, rinsing, enzymolysis, and ultrafiltration are performed to obtain bone peptide liquid; S3, mixing the bone peptide solution, chlorogenic acid grafted chitosan and transglutaminase, reacting, inactivating the enzyme, dialyzing, and drying after the dialysis is completed to obtain an antioxidant functional polypeptide; The mass ratio of the chlorogenic acid grafted chitosan and transglutaminase is 1:0.2-0.3; The mass volume ratio of the chlorogenic acid grafted chitosan and the bone peptide liquid is 1g:50mL~100mL.
2. The separation and purification method according to claim 1, characterized in that The enzymatic hydrolysis is a two-step enzymatic hydrolysis process, wherein: Neutral protease is used in the first step of enzymatic hydrolysis; In the second step of enzymatic hydrolysis, trypsin and flavor protease are used.
3. The separation and purification method according to claim 1, characterized in that: The temperature of the enzymolysis is 50°C to 60°C.
4. The separation and purification method according to claim 1, characterized in that: The molecular weight cut-off of the ultrafiltration was 2000Da.
5. The separation and purification method according to claim 1, characterized in that: The preparation method of chlorogenic acid grafted chitosan comprises the following steps: Mixing chitosan, acetic acid, chlorogenic acid and vitamin C to prepare a first mixture; The first mixture and the hydrogen peroxide solution are mixed and reacted, dialyzed, and then freeze-dried.
6. The separation and purification method according to claim 5, characterized in that: The mass ratio of chitosan to chlorogenic acid is 1:0.5-1; The mass ratio of chitosan to vitamin C is 1:0.05-0.
2.
7. The separation and purification method according to claim 5, characterized in that: The molecular weight cut-off for dialysis during the preparation of the chlorogenic acid grafted chitosan is 10000Da.
8. The separation and purification method according to claim 1, characterized in that: The reaction temperature in step S3 is 20°C to 30°C.
9. A polypeptide, characterized in that Prepared by the separation and purification method according to any one of claims 1 to 8.
10. Use of the polypeptide according to claim 9 in preparing antioxidant active substances.
Citation Information
Patent Citations
Preparation method of chicken bone paste zymolyte with antioxidant activity
CN101856367A
Method for preparing polypeptide-grafted chitosan / hydroxyapatite / pearl powder bracket
CN104031288A
Bovine bone polypeptide sustained-release preparation and preparation method thereof
CN106309372A
Preparation method of protein-polyphenol-polysaccharide covalent complex and application of protein-polyphenol-polysaccharide covalent complex
CN108719999A
Chitosan chlorogenic acid salt, preparation method and application thereof
CN108727516A
